Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 23, 2005. The report details a share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 17, 2004, and discloses changes in directors' interests related to the GlaxoSmithKline Employee Trust.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial data disclosed relates to the share buyback:
- Shares Purchased: 800,000 Ordinary Shares
- Purchase Date: March 22, 2005
- Price per Share: 1,235.34 pence
- Treasury Shares Held: 81,893,000 (post-transaction)
- Shares in Issue: 5,858,462,609 (excluding treasury shares)
Material Changes
The primary material change reported is the reduction of outstanding shares through the acquisition of 800,000 shares for treasury. Additionally, the GlaxoSmithKline Employee Trust transferred 4,000 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on March 22, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities. No specific risks or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the total cost of the 800,000 share repurchase against the stated price of 1,235.34 pence per share.
- Confirm the updated total share count (5,858,462,609 in issue) in subsequent filings.
- Review the impact of the 4,000 share transfer from the GSK Trust on the Employee Share Option Plan 1991.
- Check for any additional share buyback announcements to assess the remaining authority under the May 2004 shareholder resolution.